South Korea will invest 12 billion won in developing high-performance, liquid-fuel engines by next year as part of its space project, according to the ICT and science ministry.
The country unveiled the "Space Challenge" program in 2020 intending to invest 49.6 billion won until 2028 to secure future space industry technologies and leadership in 2030.
Of the total, the ministry has set aside a budget of 4.5 billion won this year and 7.5 billion won for 2023 to develop a 100-ton liquid-fuel engine.
The project also seeks to develop the next-generation rocket to succeed the Nuri rocket, which was equipped with 75-ton engines.
Nuri, also known as the KSLV-II, is South Korea's first homegrown space launch vehicle that successfully flew to a target altitude of 700 kilometers in October last year.
However, Nun failed to put a dummy satellite into orbit as its third-stage engine burned out sooner than expected.
South Korea plans to launch its first lunar orbiter this year.


India–U.S. Interim Trade Pact Cuts Auto Tariffs but Leaves Tesla Out
Japanese Pharmaceutical Stocks Slide as TrumpRx.gov Launch Sparks Market Concerns
SpaceX Starship Test Flight Reaches New Heights but Ends in Setback
FDA Pilot Program Eases Rules for Nicotine Pouch Makers
Gold and Silver Prices Rebound After Volatile Week Triggered by Fed Nomination
U.S.-India Trade Framework Signals Major Shift in Tariffs, Energy, and Supply Chains
Fed Governor Lisa Cook Warns Inflation Risks Remain as Rates Stay Steady
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage
Vietnam’s Trade Surplus With US Jumps as Exports Surge and China Imports Hit Record
Tabletop particle accelerator could transform medicine and materials science
NASA Cuts Boeing Starliner Missions as SpaceX Pulls Ahead
Russian Stocks End Mixed as MOEX Index Closes Flat Amid Commodity Strength
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options
Bank of Japan Signals Readiness for Near-Term Rate Hike as Inflation Nears Target
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment
China Extends Gold Buying Streak as Reserves Surge Despite Volatile Prices 



